Potential applications and impact of the adeno-associated virus (AAV) as a gene transfer vector have expanded rapidly in the last decade. Recent advances in the production of high-titer purified rAAV vector stocks have made the transition to human clinical trials a reality in the last moments of the millenium. Production improvements will be complemented in the coming years with understanding of and
The discipline of gene therapy is relatively new when compared with other fields of study. However, from the beginning, there has been a clear concept of the expectations required to bring this technology into the clinic. The field of gene therapy placed the same requirements on rAAV vectors as on other would-be vectors. These expectations included: (1) high titer production capability (suitable for human applications); (2) long term expression of the transgene; (3) no immune response to vector transduced cells; and (4) no toxicity to the patient after vector delivery. While the difficulty of high-titer rAAV vector production has overshadowed all of the other requirements, recent advances in production techniques (see below) have largely overcome this hurdle, and have found the other requirements effectively addressed. Now, definitive in vivo results establishing all of the above criteria encourage further testing of the vector system in the clinical arena. The use of AAV as a vector has been driven by the desire to exploit the unique biology of this virus. While understanding of the basic biology of AAV continues to evolve, this discussion focuses on the many recent findings that effectively expand the potential of AAV as a gene therapy vector.
To gain some perspective, it is useful to look back to 1995, at which time Catherine McKeon at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) hosted a Workshop on AAV vectors. 1 At that time, knowledge of AAV biology appeared to predict the most logical gene therapy applications to target. As a virus that often co-exists intimately with adenovirus, vector delivery to the airway appeared logical and promis- innovations in the targeting and packaging of rAAV, the design of transgene cassettes, and the host immune response to the vectors. These expected areas of progress are discussed, with special attention to clinical applications for which rAAV vectors may help close the gap towards successful gene therapy. Gene Therapy (2000) 7, 24-30. ing. As a virus capable of persistence following integration into the host cell, targeting repopulating hematopoietic stem cells, analogous to retroviral vector applications, appeared straightforward. 2 In fact, the 'Gene Expression' portion of the 1995 Workshop was comprised entirely of applications in the lung and bone marrow, save a single discussion of delivery to the CNS for Parkinson's disease. At this time, data from Flotte and During suggested the potential for persistence of rAAV genomes in vivo. Following these observations, 1996 saw the publication of two important papers, by Xiao et al 3 and Kessler et al, 4 demonstrating long-term expression in muscle tissue after a single injection of virus. Taken together, these papers showed that in vivo rAAV delivery to muscle, a largely terminally differentiated tissue, resulted in long-term (greater than 1 year) expression of marker protein (beta-Gal) 3 or of secreted protein (erythropoietin, functionally serving to drive erythropoiesis) 4 without toxicity to the animal and without eliciting a cellular immune response to the vector transduced cells. These studies initiated a stream of papers by numerous laboratories evaluating AAV's potential in vivo. Not only was it exciting to see gene after gene perform with near identical results in muscle, lung, gut, liver, CNS and eye, parallel development of AAV production capability has provided vector reagents in the abundance required for in vivo testing.
Expansion of production capacity
Along with evidence indicating that requirements 2-4 above could be met with AAV (long-term expression, no immune response and no toxicity), recent progress in rAAV production techniques predict high-titer rAAV stocks will be accomplished without the cost of contamination by wild-type AAV or helper virus. Specific limitations related to the biology of wild-type AAV lytic infection, specifically the requirement for a helper virus, coupled with traditional purification procedures (eg CsCl 2 gradients) have negatively impacted the success of rAAV production. More specifically, these include: (1) the dependence on helper adenovirus or herpes virus for lytic replication of the AAV genome, risking helper virus contamination of final rAAV stocks; (2) reliance on density gradients for purification of rAAV from lysates, because of lack of knowledge regarding AAV capsid structure or receptors; (3) poor performance of producer cell lines, due in part to the toxicity of constitutive AAV replication protein (rep) expression in most eukaryotic cells; (4) established assays for determining vector particle and transducing number. The risk of contamination with live helper virus or with structural helper virus proteins has been eliminated in rAAV production by the substitution of adenovirus (Ad) with a plasmid bearing the E2a, E4orf6 and VA helper functions and growth on HEK 293 cells which express Ad E1a and E1b. 5 The substitution of density centrifugation with the iso-osmotic and inert medium iodixanol has been adopted to decrease toxicity from aggregation of rAAV with cell lysate proteins, in addition to toxicity from residual hyperosmotic CsCl 2 . 6 Alternatively, cell lysate preparation by detergent treatment (deoxycholate) has been described: subsequent heating and freezing results in a supernatant that can be purified by affinity chromatography, even when live Ad is used for helper function. 7, 8 The identification of heparan sulfate proteoglycan as a cellular receptor for attachment and infectivity of AAV-2 8 and the generation of virion-specific monoclonal antibodies 9 has resulted in the transition to ligand affinity matrix chromatographic purification as the standard for rAAV production in most core facilities. Establishment of the infectious center assays and other reproducible quantification methods has enabled investigators to evaluate more thoroughly their starting material. 10 Additional co-receptors for AAV infection continue to be described 8, 11 and will no doubt result in further precision of purification and improved clinical safety. It is likely that the specificity and degree of purification that result from ligand affinity purification will finally allow production to move away from cumbersome and expensive transfection-dependent techniques.
At least two recent innovations have been described that predict a move away from transfection of vector and helper plasmids, and towards cell lines that will yield rAAV following simple infection with hybrid helper viruses. The utility of early rep/cap expression cell lines has been extended by the development of hybrid recombinant Ad that contain the AAV ITR/transgene cassette in the place of the Ad E1a. 12, 13 Alternatively, Conway et al 14 have developed a recombinant replication-defective herpes simplex virus (HSV) containing the AAV rep/cap, which when used to infect a cell line containing the AAV vector genome, supply both helper virus and AAV complements without requiring a transfection step.
14 The identification of the Ad helper genes predicts the eventual establishment of packaging cell lines similar to those established for retroviruses and Ad production. Finally, the future of rAAV vector production will almost certainly involve moving completely away from cell-based systems. In vitro packaging of AAV particles has been demonstrated. 15, 16 Following preparation of rep/cap-containing cell extracts and of replicating-form vector DNA, a 4-h incubation at 37°C results in in vitro synthesis of recombinant AAV particles. These particles have been Gene Therapy shown to share the same physical properties with in vivosynthesized rAAV particles including gradient density, resistance to denaturation (by chloroform, DNAse I, and heat), immunoaffinity, and dependence upon the AAV ITRs and active DNA replication for packaging. In vitro packaged rAAV/lacZ transduces mammalian cells in a manner indistinguishable from traditional vector generated in vivo. As facility with this system leads to increased understanding of the underlying components of AAV replication, it is expected that currently low titers produced in vitro (ෂ10 5 infectious particles/ml) will increase in the fashion that has been seen with cell-based rAAV production.
Improving expression cassettes
Unlike other delivery systems that have evolved into 1st, 2nd and even 3rd generation vectors, the rAAV original vector composition (145 bp terminal repeat constructs flanking the transgene of interest) appears to be the final version. This fact places the emphasis for future vector development on optimizing the transgene cassette. Improved efficiency of expression cassettes and specific clinical applications that reduce the ultimate titers of rAAV required will complement the aforementioned efforts to expand production capacity. As an example, several groups have delivered human factor IX cDNAs to C57Bl/6 mice using expression cassettes that differ principally in the promoter. Mice given rAAV/hF.IX driven by the murine Molony virus LTR (MFG) promoter produce about twice as much circulating factor IX as mice treated with an elongation factor 1 (EF-1alpha)-driven construct at comparable doses (6.3 versus 5.5 × 10 10 vector genomes per animal, respectively). 17, 18 However, rAAV transgenes driven by the LSP (liver-specific promoter), when delivered by the same route (via portal vein) as the MFG-driven construct, resulted in about five times greater expression, albeit at three times the dose. 19 Therefore, a five to six-fold reduction in vector requirement has evolved by simply optimizing the expression cassette. This will be of significant importance when phase I and II gene therapy studies move to large-scale testing. Although it may appear from this lesson that the goal should be to match a given target organ with promoters specific to that organ, the recent development of CMV/beta-actin promoters as general rAAV promoter elements with very similar vitality in muscle, liver and lung would argue against assumptions about tissuespecificity of eukaryotic promoters. 20 Finally, just as expression from presumed 'tissue-specific' promoters has at times proved to be non-tissue specific in the context of rAAV transduction, assumptions about target tissue biology may also complicate vector efficiency. For example, one might assume expression cassettes designed for muscle should have uniform efficacy in that tissue, however Pruchnic et al have recently reported that slow twitch and fast twitch skeletal muscle show differential expression following rAAV transduction. 21 While unraveling the skein of possible variables affecting each individual target application appears a humbling undertaking, the benefits of decreased vector production requirement and decreased vector exposure may be considerable. These incremental changes in novel promoter cassettes, target tissue biology and improved vector purification and production will provide AAV vector modi-fications that will continue to impact the efficiency of this delivery system in vivo.
Expanding tissue targets for expression
It is clear that the next few years will see efforts towards targeting AAV vectors to specific tissues and to engineering improved delivery and infectivity of tissues for which AAV has a natural tropism. While targeting of retrovirus and adenovirus vectors has been pursued for years, targeting of rAAV has lagged behind, partially because of deficient knowledge regarding the AAV capsid structure and surface receptors. The crystal structure of the wildtype AAV is still unknown, although some inferences can be drawn from the known capsid architecture of other mammalian parvoviruses. In addition, comparison of homology with other AAV serotypes, 22 and emerging information from genetic capsid modification (eg by insertional mutagenesis) 23 already suggest strategies for targeting that will be fruitful in the near future. More specifically, Girod et al 24 describe the insertion of a targeting peptide, designated L14, into a putative loopedout region of the AAV capsid, resulting in packaged rAAV which acquired the ability to infect L14 ligandbearing cells, despite the fact that this cell line is normally non-permissive for AAV infection. Emerging knowledge regarding the primary receptors and co-receptors for AAV has translated quickly into gains in production methods (as discussed above), and should aid re-targeting in the near future. The non-enveloped property and simplicity of the AAV virion structure (60 Vp3 subunits) lend themselves to chemical modifications that should facilitate similar goals. Utilization of capsid gene shuffling may also derive AAV vectors with new tropism as well as viral variants resistant to naturally occurring neutralizing antibody. These vector reagents will be useful for applications wherein re-administration is required. No doubt capsid tinkering will eventually become as commonplace as promoter cassette modification. It is anticipated that AAV vectors derived from these modifications will eventually supersede today's vectors for infectivity, stability, toxicity and expanded tropism.
Expanding packaging capacity
A potential rate-limiting aspect of the AAV delivery system has always been the small packaging capacity (Ͻ5 kb). Strategies are being developed that hope to expand the size of transgenes that can be delivered via rAAV vectors. These strategies include the development of hybrid viral capsid structures (eg parvovirus B19/AAV hybrids), 25 the use of expression cassettes with small promoters (including the AAV p5 promoter) 26 or promoter activity derived from the AAV ITR. 27 In addition to these logical approaches, a novel strategy developed by Xiao and colleagues employs a unique feature of AAV biology, that is, viral DNA dimerization, to direct expression from transgene sequences that exceed the 5 kb packaging capacity. 28 This approach stems from the fact that persistence of expression from rAAV vectors occurs at least in part from latent AAV proviral DNA existing in head to tail concatamers, whether integrated or in non-integrated circular forms. 3, 29 Based on this feature of AAV, a large candidate gene can be split into two segments (totaling 10 kb) and separately packaged into two individual AAV vectors. Key to this approach is the inherent ability of AAV to form concatamers fusing the 5Ј and 3Ј segments of the split gene of interest through the common vector ITR. The novel use of an intron strategy to removed the bridging ITR sequence from mature mRNA expressed from the concatameric vectors results in therapeutic product. This process relies specifically on heterodimerization (HD) of two AAV vectors when forming concatamers. In a proof of principle experiment, Xiao et al split the reporter gene beta-galactosidase into left and right half vectors, with the appropriate engineered intron splice-donor and acceptor sites. pAAVLacZleft and pAAVLacZ-right plasmids were then used for rAAV production and co-infection of 293 cells. Positive LacZ staining was seen only in the target cells that received both vectors. Further analysis demonstrated that proper heterodimer formation had taken place and the ITR junction that intervened in the head to tail concatamer was removed by mRNA processing. As a result of this approach, hetero-dimer genome vectors effectively double the packaging capacity of rAAV. This approach should allow a return to the option of full-sized promoters for large transgenes (eg CFTR cystic fibrosis), as well as packaging of such genes as dystrophin (Duchenne muscular dystrophy), dysferlin (limb girdle muscular dystrophy 2B), and Factor VIII (hemophilia A) without concern for size limitation.
Expanded demand for immune-tolerated vectors
The closing months of the 20th century, burdened with the first treatment-related death during a gene therapy trial, delivered to the entire field a sobering reminder that much remains to be learned regarding what constitutes a safe vector. Although it is tempting to assume that recombinant AAV vectors will have the same non-pathogenic behavior as the wild-type virus (wtAAV), care must be taken when implying rAAV is equivalent to wtAAV. The amount of vector being administered (Ͼ10 13 vector genomes) and the sites of delivery (eg stereotactic injections in the brain) are all examples of uncharted waters when compared with natural AAV infection of the upper respiratory tract in man. In addition, immune tolerance and the amount of variability between subjects in terms of what precipitates inflammatory reactions require examination. At this point in time, with the exception of two trials in humans, all safety data for rAAV vectors relies completely on pre-clinical studies. While encouraging, the models do not involve the natural host for wtAAV infection.
By the mid-1990s, it became clear that both humoral and cell-mediated immune responses can limit sustained expression from gene therapy vectors. Examining different target tissues (liver, lung) it was apparent that cytotoxic T-lymphocytes eliminated transduced cells following expression of transgenes after use of certain viral vectors. Immune responses to adenovirus transduction and to rAAV transduction were compared directly in a 1996 study. Using the lacZ gene, Xiao et al 3 demonstrated that both adenovirus and adeno-associated viruses transduced mature murine muscle. As expected from multiple previous studies, a vigorous early cell-mediated immune response resulted in the elimination by 3 weeks postinfection (PI) of all of the adenovirus-transduced cells. + T H2 IL-10 response could be demonstrated against the transgene, humoral immune stimulation was primarily in response to the rAAV capsid. The same group has gone on to examine the role of antigenpresenting cells (APCs) in rAAV-mediated transgene persistence in muscle. AAVlacZ-transduced antigenpresenting cells were unable to elicit transgene immunity in adoptive transfer experiments. 31 Specifically, the dendritic cell population of APCs appears to exhibit a block for transduction by rAAV vectors, a block that is not seen or can be overcome in some quiescent cell types, including muscle and brain.
A significant caveat to these conclusions is that the cellular immune response to rAAV appears to depend on the route of administration. Brockstedt et al 32 have used rAAV encoding ovalbumin to look at CTL and antibody response in C57Bl/6 mice following intraperitoneal, intravenous, subcutaneous, or intramuscular delivery. The intramuscular delivery was the only route that did not develop CTL responses, while all routes led to antibody production against the transgene and the vector. Even the immune-protection in muscle has not been universally seen, as some have suggested that intramuscular antigen delivery with AAV vectors is a promising route for immunization, based on observation of antibody and CTL responses following i.m. vaccination. 33 In addition, Hermonat and colleagues have demonstrated successful AAV transduction in monocytes before their differentiation into mature APCs. 12 Investigation of these immune mechanisms will be critical over the next few years, as confounding data from strain-dependent variations in murine immune response will be overcome by superior animal models, and results of human trials will become available.
Detailed analysis of immune responses to rAAV in large animal models is sparse, although primate responses to AAV delivery to the airway have been documented. In one series, rhesus macaques were treated with wild-type AAV intranasally, intravenously, and intramuscularly. 34 Animals in each group could be shown to have low levels of transgene sequences persisting at 21 days. Explanted lymphocytes stimulated ex vivo did not proliferate in response to AAV capsid antigen, however, unless the animal had also been exposed to helper adenovirus at the time of initial AAV exposure. In addition, the animals exposed to wtAAV only by the intranasal route did not demonstrate a significant increase in anti-AAV neutralizing antibodies, though wtAAV exposure by i.m., i.v., or by intranasal administration admixed with adenovirus did result in prompt anti-AAV antibodies. These results, along with the lack of toxic reactions by Gene Therapy primates and humans in rAAV/CFTR trials (see below), are very encouraging, given that the rhesus macaque is immunologically a good mirror for human responses.
Finally, the significance of anti-AAV antibodies, which have a very high seroprevalence in humans, will be elucidated in the coming years. Up to 80% of adults are seropositive for antibodies to AAV, with antibodies against the AAV2 serotype being the most common. 35 Recently, in vitro measures of lymphocyte activation to AAV-2 were performed on a cohort of 74 adults (45 healthy subjects and 29 patients with cystic fibrosis). ELISA-positive anti-AAV antibodies were detected in 96% of subjects, although only 1/3 of these demonstrated neutralizing antibodies. Peripheral blood mononuclear cells were analyzed for lymphoproliferative response, with only 6% of subjects demonstrating a significant LPR. Interferongamma was detected in 6% of subjects and IL-10 in 12% of subjects. 36 Given that humans are the natural host of the AAV2, the advent of human clinical trials will make clear the significance of antibody responses to AAV serotypes, as relates to initial rAAV vector exposure and potentially re-administration. This knowledge will be augmented by elucidating the capsid architecture of AAV2 and of recently described alternative serotypes. 22, [37] [38] [39] If, for instance, the bulk of antibody responses proves to be directed at specific moieties on the AAV capsid, a block to re-administration may be overcome by selective capsid modifications as described above.
Expanded clinical applications/'Nichespecific' AAV gene therapy
Applications for DNA delivery via recombinant AAV to almost every tissue of the body, and the recent enrollments on rAAV clinical gene therapy trials, seem to signal that this virus will be widely tested in humans over the next couple of years. Nevertheless, it is probable that rAAV vectors will find specific niches wherein they will be most efficacious, although these niches may appear somewhat different from those put forward at the 1995 NIDDK Workshop. Some predictions are possible: (1) Adeno-associated viruses, with their characteristic lag phase to expression, will best suit applications where persistence of expression is the priority, as for long-term expression of secreted proteins. (2) AAV has special utility in certain quiescent tissues such as the brain and the muscle. (3) AAV should be useful in tissues that cannot tolerate even minor amounts of inflammation. While such a discussion is necessarily exclusive, it is worthwhile to review several cogent examples that have demonstrated safety in large animals or that near clinical application.
The utility of AAV for persistent and even regulatable expression of secreted proteins, which function systemically or after travelling to a target organ, makes rAAV vectors ideal for protein deficiencies such as the hemophilias and many inborn errors of metabolism. The expression of erythropoietin from muscle has been an excellent paradigm for these qualities. 4, 40, 41 Erythropoietin expression from muscle occurs despite the fact that the vast majority of muscle tissue is terminally differentiated. Secretion persists and is clearly reflected in supraphysiologic erythropoiesis in mice, which can be regulated between normal and polycythemic hematocrit levels by the inclusion of a tetracycline reverse transactiv-Gene Therapy ator element within the expression cassette. Providing that the erythropoietin gene of the proper species is used, expression in mice and in baboons has been safe and effective. To some extent, rAAV/Epo is an elegant proof of concept, but suffers from relatively obtuse clinical applications, given that anemic chronic renal failure patients and thalassemic patients (who suffer from unbalanced rather than absent hemoglobin production) may not be ideal pioneers for gene therapy applications.
A very similar strategy has been used to express serum alpha-1 antitrypsin in mice at levels that would be protective from emphysema in humans (ෂ800 g/ml).
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Although very high doses were used in the published mouse studies (10 13 vector genomes per mouse), cellmediated immune responses (as assayed by examining for lymphocyte proliferation in response to antigenic stimulation) were absent. Humoral responses varied with the targeted mouse strain. Full histologic review showed no organ toxicity or inflammation. Rodent data from rAAV/A 1 AT delivery to muscle, liver and lung, all show serum levels well above what are the defined levels for correction established for the FDA-approved protein replacement product. Baboon studies are forthcoming, and will yield important primate safety information (personal communication, TR Flotte). It is clear that evaluation of AAV gene therapy using muscle as a platform for secreted gene product is well on its way, and if successful, may prove an approach for relatively noninvasive gene therapy administration.
The brain, or more specifically, the neurons are also a terminally differentiated tissue that has been enthusiastically targeted for rAAV gene therapy, as shown by over 30 original research publications pursuing this goal since 1996 alone. 10 The brain is another example of a target tissue in which very little inflammation can be tolerated before clinical consequences arise, yielding a significant advantage to the least immunogenic vector possible. AAV transduction of the brain with a beta-glucuronidase (GUSB) gene has recently been used as a tool for elucidating the pathology of the lysosomal storage disease mucopolysaccharidosis type VII (MPS VII), as well as a potential therapeutic strategy. 42 Serum levels of greater than 1% of normal GUSB appear sufficient to reverse the multiorgan storage disease. Newborn MPS VII mice injected intravenously with rAAV/GUSB were previously reported to demonstrate 1-1000% of normal levels of GUSB in the heart, lung, brain, and kidney for the length of the study (4 months after injection). Perhaps more provocative, however, are recent studies in which MPS VII newborns were injected intracranially with rAAV/GUSB. Although transduction in these animals could only be demonstrated in cells near the site of injection, histopathological analysis showed that lysosomal storage disease was essentially eliminated throughout the brain. In addition, a degree of cognitive protection could be demonstrated, as the treated animals outperformed sham-treated animals in the Morris Water Maze test. These results have helped the investigators dissect the natural timing of cognitive damage in this condition as well as to predict that direct correction of brain lysosomal storage (rather than simply correction of systemic disease) will be required for normal cognitive development. rAAV-mediated correction of MPS II and glycogen storage disease II are also under development.
The eye, in many ways analogous to the brain as a neural tissue with barriers against circulating proteins, has also become a favored target of rAAV gene delivery. 10 The retina represents another area where even minimal host inflammatory response results in marked functional deficits. A representative application is in retinitis pigmentosa (RP). In encouraging 'proof-of-concept' animal models experiments, rAAV delivered ribozymes designed against the P23H substitution mutant in the rhodopsin gene, the most common cause of autosomal dominant RP in humans, resulting in preservation of photoreceptors in a transgenic rat P23H RP model for more than 8 months 43 (also, personal communication, WW Hauswirth). Rescue to approximately 80% of normal was confirmed cellularly by preservation of photoreceptor morphology, functionally by electroretinographic (ERG) analysis, and molecularly by specific reduction in mutant mRNA levels. It is anticipated that clinical trials targeting these tissues will begin within the next 3 years, and hopefully perform with the same efficacy as seen in the animal models.
By 1995, at least two clinical trials for cystic fibrosis using DNA viral vectors had been limited by local inflammatory responses in the upper airway. Despite evidence that entry into mucus-laden apical surfaces of airway epithelium is a difficult barrier for the rAAV, the use of this vector for delivery to the airway continues to be pursued enthusiastically, due in part to the expectation that vector-related inflammation will be limited. In a very thorough primate study reported in 1996, investigators delivered AAV-CFTR bronchoscopically to the right lower lobe of the lungs of 10 rhesus macaques (with four vehicle-only controls). 44 Pulmonary function testing, arterial blood gas analysis, chest radiographs, bronchoalveolar lavage fluid analysis including cell counts and examination for inflammatory cytokines (IL-6 and IL-8), and complete tissue histopathological analysis revealed no differences between rAAV-treated macaques and controls despite persistence of transgene (as measured by PCR) in the pulmonic tree, as well as several extrapulmonary sites. This study, along with the primate study by Hernandez et al (see above) and a recent paper evaluating similar parameters following repeated AAV delivery to rabbit airways, 45 represent the most complete preclinical animal data regarding site-specific (airway) inflammatory responses to rAAV vectors. Moreover, there have now been over 50 humans with cystic fibrosis who have received AAV-CFTR vectors to the upper airway (sinuses) or the lower airway (via bronchoscopy, and soon, aerosolized vector) with no evidence of any vector-related adverse events 46 (also personal communication, TR Flotte).
Analogous to the chronic inflammatory state of the lung in cystic fibrosis, many conditions that would benefit from liver transduction may be associated with underlying chronic liver inflammation. Such clinical conditions are a natural choice for AAV vectors, which transduce liver with relative efficiency. For example, liver-directed therapy for hemophilia using AAV is expected to enter the clinic in the very near future, and is a likely choice of vector for this patient population, the great majority of whom are carriers of hepatitis C virus.
Results from the ongoing rAAV/F.IX trials for correction of hemophilia B are awaited with much anticipation. Full therapeutic correction in mouse models of hemophilia B was initially demonstrated using rAAV delivery to either the liver (portal vein) or to skeletal muscle. 35 Three groups have now reported the safe transfer of the Factor IX gene to dogs of the Chapel Hill strain of hemophilia B canines without any adverse treatment-related events (total of nine dogs). 18, 35, 47, 48 Following either intramuscular (up to 60 individual i.m. injections) or intraportal delivery, levels of canine F.IX equivalent to approximately 1-2% of normal human (69-140 ng/ml) were reported in the three highest-responding dogs, with detectable canine F.IX produced in all dogs (baseline = 0 ng/ml in this model of severe human hemophilia). Doses given to the muscle were on the order of 1.5-2 logs higher to achieve comparable results, although liver and muscle expression cassettes did contain different promoters. This level of correction, if achieved in humans, would convert a severe hemophiliac to a moderate hemophiliac, with a much less fragile bleeding phenotype. Moreover, when delivered to the muscle, rAAV genomes were only detected in the target site and draining lymph node in two dogs examined by PCR of multiple tissues; RT-PCR of one of these animals showed vector-specific mRNA products in the liver as well as the injection site. No transmission to the gonads or germline was seen in the canines examined, or in a more rigorous series of rabbit experiments with i.m. rAAV/F.IX performed by one of the investigators (reported by Katherine High, 1999 Congress of the International Society of Thrombosis and Hemostasis, Washington, DC). While these results all reinforce the perceived safety of this vector, two dogs were noted to develop antibodies to the transduced F.IX product. One of these was not inhibitory for clotting activity, disappeared within 2 weeks, and was essentially clinically insignificant. One dog, however, developed a transient (lasting about 3 months) but significant Bethesda inhibitor antibody against canine factor IX. Persistent naturally occurring inhibitor antibodies are a serious complication of treatment of human hemophilia. These studies remind us that a complex and poorly understood interplay of vector/transgene, route of administration, tissue transduced, protein product, host immune background, and underlying gene defect is involved in antigen presentation and 'self' versus 'nonself' recognition. Initial safety results from the rAAV/human F.IX clinical trial are promising. Of three patients treated intramuscularly (the first now several months from treatment) none have experienced any toxicity, none have developed anti-F.IX antibodies, and none show germline transmission on assay of sperm samples (personal communication, K High). Nevertheless, the future for recombinant adeno-associated virus gene therapy is justifiably viewed with caution, as well as enthusiastic optimism.
